Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119713 · ClinicalTrials.gov registry record
Autoimmunity After Checkpoint Blockade
A clinical trial of Cancer and Oncology, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT04119713 is a study of Cancer and Oncology that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 600 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04119713, a study of Cancer and Oncology, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Conditions Studied
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04119713
The ClinicalTrials.gov registry entry for NCT04119713 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT04119713 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04119713 about?
NCT04119713 is a clinical study titled "Autoimmunity After Checkpoint Blockade". The purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint i...
What is the current status of trial NCT04119713?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2020-02-24. Estimated completion is 2026-06-30.
What conditions does trial NCT04119713 study?
This clinical trial studies the following conditions: Cancer, Oncology, Autoimmunity, Immunotoxicity.
Who is sponsoring clinical trial NCT04119713?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04119713 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.